Second Sight Medical Products Inc. (NASDAQ:EYES) shares dropped 2.4% during trading on Thursday . The stock traded as low as $4.08 and last traded at $4.08, with a volume of 166,501 shares traded. The stock had previously closed at $4.18.

Separately, Zacks Investment Research cut Second Sight Medical Products from a “hold” rating to a “sell” rating in a research report on Monday, April 18th.

The stock’s 50 day moving average price is $3.83 and its 200-day moving average price is $4.55. The stock’s market cap is $149.19 million.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period in the prior year, the company earned ($0.12) earnings per share. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.38 million. The firm’s quarterly revenue was down 38.2% on a year-over-year basis. On average, equities analysts predict that Second Sight Medical Products Inc. will post ($0.65) EPS for the current year.

In related news, Chairman Robert J. Greenberg sold 8,223 shares of the stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $5.27, for a total transaction of $43,335.21. Following the completion of the transaction, the chairman now directly owns 181,134 shares of the company’s stock, valued at $954,576.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Robert J. Greenberg sold 8,571 shares of the stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total value of $35,141.10. Following the transaction, the chairman now directly owns 172,911 shares of the company’s stock, valued at $708,935.10. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Second Sight Medical Products stock. Zeke Capital Advisors LLC purchased a new stake in shares of Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products comprises about 2.5% of Zeke Capital Advisors LLC’s investment portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned about 1.38% of Second Sight Medical Products as of its most recent SEC filing.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.